Home -> Law Blog Directory -> Patent Law Blogs -> Patent Docs

Patent Law

: Patent Docs

Deloitte White Paper Addresses Unintended Consequences of Follow-on Biologic Regulatory Pathway

By Donald Zuhn, Kevin Noonan, Chris Singer, Sherri Oslick, and Jason Derry

By Donald Zuhn -- Last spring, Patent Docs discussed pending follow-on biologics legislation with California Healthcare Institute (CHI) president and CEO Dr. David Gollaher (see "CHI CEO on Patent Reform and Follow-on Biologics Legislation"). During the discussion, Dr. Gollaher mentioned that Deloitte Consulting LLP (a subsidiary of CHI member Deloitte LLP) had released its own white paper on follow-on biologics entitled "Avoiding No Man's Land: Potential Unintended Consequences of Follow-on Biologics." The Deloitte paper is a recent addition to a growing collection of publications that address the potential impact of implementing a follow-on biologics regulatory pathway in the United States....

Full post as published by Patent Docs on August 28, 2009 (boomark / email).